James McAvoy, MD
Family Medicine · Elberton, GANPI 1215917901
Payments from drug & device makers
Across 259 payments — averaging $18.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$773
- Boston Scientific$752
- Novo Nordisk$613
- Shield Therapeutics Inc$408
- Novartis$274
- Pfizer$250
- plus $2K from 29 others
What the payments were for
- Food & beverage$4,694100%
- Education$10%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 58 | $773 |
| Boston Scientific | 3 | $752 |
| Novo Nordisk | 60 | $613 |
| Shield Therapeutics Inc | 8 | $408 |
| Novartis | 18 | $274 |
| Pfizer | 14 | $250 |
| GSK | 11 | $188 |
| Lilly USA, LLC | 12 | $180 |
| Boehringer Ingelheim | 9 | $167 |
| Astellas Pharma US Inc | 8 | $157 |
| Merck | 9 | $123 |
| Amgen | 6 | $102 |
| AstraZeneca | 6 | $87 |
| Nestle Healthcare Nutrition Inc. | 5 | $66 |
| Sanofi-aventis U.S. LLC | 3 | $55 |
| Dexcom, Inc. | 3 | $48 |
| Biogen | 3 | $45 |
| Corcept Therapeutics | 2 | $45 |
| Johnson & Johnson | 3 | $42 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $34 |
| Teva Pharmaceuticals USA, Inc. | 2 | $29 |
| Hikma Pharmaceuticals USA | 1 | $23 |
| Eyevance Pharmaceuticals LLC | 1 | $23 |
| Lundbeck LLC | 1 | $23 |
| Otsuka America Pharmaceutical, Inc. | 1 | $23 |
| Abbott | 1 | $22 |
| Genentech USA, Inc. | 1 | $21 |
| Exact Sciences | 1 | $21 |
| Xeris Pharmaceuticals, Inc. | 1 | $19 |
| E.r. Squibb & Sons, L.L.C. | 1 | $18 |
| Scilex Pharmaceuticals Inc. | 1 | $18 |
| Mylan Specialty L.p. | 1 | $14 |
| Kowa Pharmaceuticals America, Inc. | 1 | $14 |
| Bayer | 1 | $14 |
| Sumitomo Pharma America, Inc. | 1 | $1 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,695 in reported general payments places this provider in the 80th percentile of 3,111 family medicine providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 917 | $361,472 |
| OzempicSemaglutide | 250 | $266,179 |
| FarxigaDapagliflozin Propanediol | 316 | $155,490 |
| TrulicityDulaglutide | 154 | $142,129 |
| JardianceEmpagliflozin | 197 | $115,318 |
| XareltoRivaroxaban | 204 | $89,153 |
| JanuviaSitagliptin Phosphate | 141 | $75,256 |
| RybelsusSemaglutide | 41 | $51,619 |
| MounjaroTirzepatide | 51 | $51,168 |
| Tresiba Flextouch U-100Insulin Degludec | 105 | $47,457 |
| XifaxanRifaximin | 11 | $34,507 |
| Enbrel SureclickEtanercept | 12 | $33,224 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 38 | $31,200 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 41 | $27,607 |
| Risperdal ConstaRisperidone Microspheres | 23 | $26,996 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $250 | $361,472917 claims |
| Novo NordiskOzempic, Rybelsus, Levemir | $613 | $325,499319 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $180 | $193,297205 claims |
| AstraZenecaFarxiga, Symbicort | $87 | $168,711373 claims |
| Boehringer IngelheimJardiance, Combivent Respimat, Stiolto Respimat | $167 | $134,535233 claims |
| Johnson & JohnsonXarelto, Risperdal Consta | $42 | $116,149227 claims |
| MerckJanuvia, Belsomra | $123 | $83,488162 claims |
| GSKTrelegy Ellipta, Incruse Ellipta, Breo Ellipta | $188 | $46,21490 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $34 | $34,50711 claims |
| AbbVieCreon, Linzess | $773 | $29,50191 claims |
| NovartisEntresto | $274 | $13,73220 claims |
| Sanofi-aventis U.S. LLCLantus | $55 | $12,410129 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 3,111 family medicine providers in Georgia.
Other family medicine in Elberton
- Joseph SurberColumbus$16.6M
- Angela RitterGainesville$15.8M
- Jeffrey KingsleyColumbus$8.1M
- Christopher OldfieldSavannah$6.4M
- Darrell MurrayAtlanta$3.9M
- Ben ThomasAtlanta$3.2M
- Debbie HaginsSavannah$2.1M
- Aziz PiraniLilburn$2.1M
- Nadia CameronAtlanta$2.1M
- John LentzSnellville$1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.